Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs03835085

Ligand	Ligand name	Chain	PDB	Tanimoto
CAV	5-AMINO-6-CYCLOHEXYL-3,4-DIHYDROXY-2-ISOPROPYL-HEXANOIC ACID	A,B,I	1HIV	0.7
CAV	5-AMINO-6-CYCLOHEXYL-3,4-DIHYDROXY-2-ISOPROPYL-HEXANOIC ACID	I	1IVP	0.7
NAY	6,7,8,9-TETRAHYDROXY-5-METHYLCARBOXAMIDO-2-OXONONANOIC ACID	A,C	1F74	0.71
FEB	N~2~-[(3R)-3-hydroxydodecanoyl]-L-asparaginyl-N~1~-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-L-glutamamide	2,H,K,N,V,Y	3D29	0.71
IVS	3-HYDROXY-6-METHYL-4-(3-METHYL-2-(3-METHYL-2-(3-METHYL-BUTYRYLAMINO)-BUTYRYLAMINO)-BUTYRYLAMINO)-HEPTANOIC ACID ETHYL ESTER	A,B	1ME6	0.72
ABX	5-[1-(ACETYLAMINO)-3-METHYLBUTYL]-4-(METHOXYCARBONYL)PROLINE	A	1XOE	0.71
NAV	6,7,8,9-TETRAHYDROXY-5-METHYLCARBOXAMIDO-4-OXONONANOIC ACID	A,C	1F7B	0.7
BCZ	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID	A	1L7G	0.93
BCZ	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID	A	2HTU	0.93
BCZ	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID	A	2F10	0.93
BCZ	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID	A	1L7H	0.93
BCZ	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID	A	1L7F	0.93
NAU	4,4,6,7,8,9-HEXAHYDROXY-5-METHYLCARBOXAMIDONONANOIC ACID	A,C	1F7B	0.71
AMK	(S)-4-AMINO-4-{(S)-1-[(S)-2-CARBAMOYL-1-((S)-1-{(S)-[(1R,2R)-2-((S)-1-CARBOXY-ETHYLCARBAMOYL)-CYCLOPENTYL]-HYDROXY-METHYL}-3-METHYL-BUTYLCARBAMOYL)-ETHYLCARBAMOYL]-2-METHYL-PROPYLCARBAMOYL}-BUTYRIC ACID	A,B,C	1YM4	0.76
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A	3EMY	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A	2H6T	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1LS5	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1SME	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,C	1W6I	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1XDH	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	2QZX	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A	1IZE	0.75
IHN	N-(3-methylbutanoyl)-L-valyl-N-[(1R,2R)-4-{[(1R)-2-({(1R)-1-[(1R)-2-carboxy-1-hydroxyethyl]-3-methylbutyl}amino)-1-methyl-2-oxoethyl]amino}-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-L-valinamide	A,B	1M43	0.75
AR9	(2R,4S)-N-butyl-4-[(2S,5S,7R)-2,7-dimethyl-3,15-dioxo-1,4-diazacyclopentadecan-5-yl]-4-hydroxy-2-methylbutanamide	A,B,C	3DV1	0.7